<p>ImmuCell Corporation（纳斯达克代码：ICCC - 获取免费报告）在 12 月份的空头头寸大幅增长。截至 12 月 15 日，空头头寸总计为 15,418 股，比 11 月 30 日的 6,239 股增长了 147.1%。目前，该公司的 0.2% 股份被做空。根据 18,731 股的平均交易量，当前的覆盖天数比率为 0.8 天。</p>
<h2>华尔街分析师观点</h2>
<p>另外，Weiss Ratings 在周一的报告中重申了对 ImmuCell 股票的 “卖出（d+）” 评级。一位股票研究分析师对该股票给予了卖出评级，根据 MarketBeat.com 的数据，ImmuCell 的平均评级为 “卖出”。</p>
<p><strong>查看我们对 ICCC 的最新股票分析</strong></p>
<h2>ImmuCell 价格表现</h2>
<p>周五午盘交易中，ICCC 的股票上涨了 0.32 美元，达到了 6.12 美元。该股票的交易量为 336,206 股，而其平均交易量为 20,020 股。该公司的 50 日移动平均为 5.69 美元，200 日移动平均为 6.15 美元。公司的债务与股本比率为 0.27，速动比率为 1.76，流动比率为 4.21。该公司的市值为 5539 万美元，市盈率为 23.54，贝塔值为 0.20。ImmuCell 的 12 个月低点为 4.28 美元，12 个月高点为 7.60 美元。</p>
<p>ImmuCell（纳斯达克代码：ICCC - 获取免费报告）最近于 11 月 13 日发布了其财报。这家生物技术公司报告了该季度每股收益为（0.02）美元。ImmuCell 的净利润率为 8.37%，股本回报率为 8.00%。该公司该季度的收入为 551 万美元。</p>
<h2>ImmuCell 的机构交易</h2>
<p>一家机构投资者最近增加了对 ImmuCell 股票的持仓。根据该公司最近向证券交易委员会提交的 13F 文件，Geode Capital Management LLC 在第二季度将其在 ImmuCell Corporation（纳斯达克代码：ICCC - 免费报告）的持股增加了 4.2%。该机构投资者在此期间购买了 2,907 股后，持有 71,852 股生物技术公司的股票。根据其最近的 SEC 文件，Geode Capital Management LLC 持有的 ImmuCell 股份价值 50 万美元，占该公司股份的 0.79%。机构投资者持有该公司 13.47% 的股份。</p>
<h2>关于 ImmuCell</h2>
<p>（获取免费报告）</p>
<p>ImmuCell Corporation（纳斯达克代码：ICCC）是一家生物技术公司，开发、制造和销售旨在增强奶牛和肉牛健康的免疫产品和诊断试剂。公司总部位于缅因州波特兰，专注于通过其被动免疫解决方案和兽医诊断产品支持群体健康管理。</p>
<p>该公司的旗舰产品 CalfGuard 天然初乳补充剂旨在促进新生小牛抗体的被动转移，并减少新生疾病的发生率。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 ImmuCell 更好</li>
<li>你知道亚马逊计划在 1 月 1 日做什么吗？</li>
<li>开火正式开始……</li>
<li>华盛顿准备开战</li>
<li>你的 “出生权索赔” 刚刚被激活</li>
<li>华尔街股票挑选者命名 2026 年第一只股票</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 ImmuCell 吗？</h2>
<p>在你考虑 ImmuCell 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 ImmuCell 并不在名单上。</p>
<p>尽管 ImmuCell 目前在分析师中被评为卖出评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ICCC

<p>ImmuCell Corporation（纳斯达克代码：ICCC）在 12 月份的空头头寸增加了 147.1%，总计达到 15,418 股。覆盖天数比率为 0.8 天，卖空股份占比为 0.2%。Weiss Ratings 重申了 “卖出” 评级。该股票上涨了 0.32 美元，报 6.12 美元，市值为 5539 万美元。机构投资者持有该股票的 13.47%。ImmuCell 专注于乳牛和肉牛的动物健康产品</p>

<p>ImmuCell Corporation (NASDAQ:ICCC - Get Free Report) was the target of a large growth in short interest during the month of December. As of December 15th, there was short interest totaling 15,418 shares, a growth of 147.1% from the November 30th total of 6,239 shares. Currently, 0.2% of the shares of the company are short sold. Based on an average trading volume of 18,731 shares, the days-to-cover ratio is presently 0.8 days. Based on an average trading volume of 18,731 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.2% of the shares of the company are short sold.</p>
<div class="lb-trans"><p>ImmuCell Corporation（纳斯达克代码：ICCC - 获取免费报告）在 12 月份的空头头寸大幅增长。截至 12 月 15 日，空头头寸总计为 15,418 股，比 11 月 30 日的 6,239 股增长了 147.1%。目前，该公司的 0.2% 股份被做空。根据 18,731 股的平均交易量，当前的覆盖天数比率为 0.8 天。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Separately, Weiss Ratings reaffirmed a &#34;sell (d+)&#34; rating on shares of ImmuCell in a report on Monday. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, ImmuCell has an average rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在周一的报告中重申了对 ImmuCell 股票的 “卖出（d+）” 评级。一位股票研究分析师对该股票给予了卖出评级，根据 MarketBeat.com 的数据，ImmuCell 的平均评级为 “卖出”。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on ICCC</strong></p>
<div class="lb-trans"><p><strong>查看我们对 ICCC 的最新股票分析</strong></p>
</div><h2>ImmuCell Price Performance</h2>
<div class="lb-trans"><h2>ImmuCell 价格表现</h2>
</div><p>Shares of ICCC traded up $0.32 during mid-day trading on Friday, reaching $6.12. The stock had a trading volume of 336,206 shares, compared to its average volume of 20,020. The business has a fifty day moving average of $5.69 and a 200 day moving average of $6.15. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.76 and a current ratio of 4.21. The firm has a market cap of $55.39 million, a price-to-earnings ratio of 23.54 and a beta of 0.20. ImmuCell has a 12 month low of $4.28 and a 12 month high of $7.60.</p>
<div class="lb-trans"><p>周五午盘交易中，ICCC 的股票上涨了 0.32 美元，达到了 6.12 美元。该股票的交易量为 336,206 股，而其平均交易量为 20,020 股。该公司的 50 日移动平均为 5.69 美元，200 日移动平均为 6.15 美元。公司的债务与股本比率为 0.27，速动比率为 1.76，流动比率为 4.21。该公司的市值为 5539 万美元，市盈率为 23.54，贝塔值为 0.20。ImmuCell 的 12 个月低点为 4.28 美元，12 个月高点为 7.60 美元。</p>
</div><p>ImmuCell (NASDAQ:ICCC - Get Free Report) last released its earnings results on Thursday, November 13th. The biotechnology company reported ($0.02) earnings per share for the quarter. ImmuCell had a net margin of 8.37% and a return on equity of 8.00%. The firm had revenue of $5.51 million for the quarter.</p>
<div class="lb-trans"><p>ImmuCell（纳斯达克代码：ICCC - 获取免费报告）最近于 11 月 13 日发布了其财报。这家生物技术公司报告了该季度每股收益为（0.02）美元。ImmuCell 的净利润率为 8.37%，股本回报率为 8.00%。该公司该季度的收入为 551 万美元。</p>
</div><h2>Institutional Trading of ImmuCell</h2>
<div class="lb-trans"><h2>ImmuCell 的机构交易</h2>
</div><p>An institutional investor recently raised its position in ImmuCell stock. Geode Capital Management LLC increased its holdings in ImmuCell Corporation (NASDAQ:ICCC - Free Report) by 4.2% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 71,852 shares of the biotechnology company's stock after purchasing an additional 2,907 shares during the period. Geode Capital Management LLC owned 0.79% of ImmuCell worth $500,000 as of its most recent SEC filing. Institutional investors own 13.47% of the company's stock.</p>
<div class="lb-trans"><p>一家机构投资者最近增加了对 ImmuCell 股票的持仓。根据该公司最近向证券交易委员会提交的 13F 文件，Geode Capital Management LLC 在第二季度将其在 ImmuCell Corporation（纳斯达克代码：ICCC - 免费报告）的持股增加了 4.2%。该机构投资者在此期间购买了 2,907 股后，持有 71,852 股生物技术公司的股票。根据其最近的 SEC 文件，Geode Capital Management LLC 持有的 ImmuCell 股份价值 50 万美元，占该公司股份的 0.79%。机构投资者持有该公司 13.47% 的股份。</p>
</div><h2>About ImmuCell</h2>
<div class="lb-trans"><h2>关于 ImmuCell</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>ImmuCell Corporation NASDAQ: ICCC is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.</p>
<div class="lb-trans"><p>ImmuCell Corporation（纳斯达克代码：ICCC）是一家生物技术公司，开发、制造和销售旨在增强奶牛和肉牛健康的免疫产品和诊断试剂。公司总部位于缅因州波特兰，专注于通过其被动免疫解决方案和兽医诊断产品支持群体健康管理。</p>
</div><p>The company's flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.</p>
<div class="lb-trans"><p>该公司的旗舰产品 CalfGuard 天然初乳补充剂旨在促进新生小牛抗体的被动转移，并减少新生疾病的发生率。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than ImmuCell</li>
<li>Do you know what Amazon is planning for January 1?</li>
<li>Shots officially fired…</li>
<li>Washington prepares for war</li>
<li>Your “birthright claim” just got activated</li>
<li>Wall Street Stockpicker Names #1 Stock of 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 ImmuCell 更好</li>
<li>你知道亚马逊计划在 1 月 1 日做什么吗？</li>
<li>开火正式开始……</li>
<li>华盛顿准备开战</li>
<li>你的 “出生权索赔” 刚刚被激活</li>
<li>华尔街股票挑选者命名 2026 年第一只股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in ImmuCell Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 ImmuCell 吗？</h2>
</div><p>Before you consider ImmuCell, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 ImmuCell 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuCell wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 ImmuCell 并不在名单上。</p>
</div><p>While ImmuCell currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 ImmuCell 目前在分析师中被评为卖出评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

ImmuCell 公司（NASDAQ: ICCC）在 12 月份的空头头寸增长了 147.1%